The activity of smooth and non-muscle myosin II is regulated by phosphorylation of the regulatory light chain (RLC) at ser19. The dephosphorylated state of full-length monomeric myosin is characterized by an asymmetric intramolecular head-head interaction that completely inhibits the ATPase activity, accompanied by a hairpin fold of the tail, which prevents filament assembly. The mechanism by which ser19 phosphorylation disrupts these head-head interactions is unknown. Computational modeling (Tama et al., 2005. J. Mol. Biol. 345, 837-854) suggested that formation of the inhibited state is characterized by both torsional and bending motions about the myosin heavy chain (HC) at a location between the RLC and the essential light chain (ELC). Based on this model, placement of the regulatory domain at this locus might alter relative motions between the ELC and the RLC and thereby disrupt the inhibited state. Here we derive an atomic model based on this hypothesis for the phosphorylated state of the smooth muscle myosin light chain domain (LCD). We use a homology model for the structure of the RLC and a largely a-helical structure for the regulatory domain. This model predicts a set of specific interactions between the regulatory domain and both the myosin HC and the ELC. Site directed mutagenesis combined with ATPase and motility assays was used to show that interactions between the highly basic N-terminus of the RLC with acidic residues on helix-A of the ELC are required for phosphorylation to activate smooth muscle myosin. These sites are well conserved in all the myosin II ELC sequences examined despite the lack of known interacting partners and when substituted, are usually substituted with aspartic acid. Supported by NIH grants AR47421, AR53975 and HL38113 and RR12255. The A1 light chain of rabbit skeletal myosin possesses a unique N-terminal extension of~40 amino acids which is lacking in A2. A C-terminal block of 140 amino acids is identical to both. The primary structures are completed by a small, non-identical peptide which is sandwiched between the above two sections of A1 and which is N-terminal in A2. The effect which A1 and A2 have on the product release step has been investigated by double-mixing stopped-flow in conjunction with a fluorescent phosphate binding protein (Buffer, 5mM MOPS, 2mM Mg acetate, pH 7). Rabbit skeletal myosin-S1 was chromatographically separated into A1 and A2 containing fractions. A slight excess of myosin-S1 over nucleotide was used in the first mix to ensure complete binding of the latter as well as a single turnover. After a 2 s delay to assure that ATP binding was complete, thin filaments (þCa) were combined with the myosin-nucleotide mixture (M-ATP Û M-ADP-Pi) in the second mix. The dominant component of the observed biphasic increase in fluorescence corresponds to Pi release from AM-ADP-Pi. Hyperbolic fits of the dependence of the rate upon the thin filament give maximum rates of: 80 s-1 (S1A1) and 139 s-1 (S1A2) and apparent binding constants of 10 mM (S1A1) and 72 mM (S1A2). The rates of phosphate dissociation are 4-5 more rapid than the steady state measurements of 20 s-1 (A1) and 36 s-1 (A2) and therefore cannot limit the rate of ATP hydrolysis. It is also evident that the N-terminal extension strengthens light chain affinity. University of Washington, Seattle, WA, USA, 2 University of California, San Diego, San Diego, CA, USA. The R21C mutation in cTnI, associated with hypertrophic cardiomyopathy (HCM), is the only known mutation within N-terminus of cTnI. The mechanisms by which this mutation leads to heart failure, and how this mutation affects PKA regulation of cTn function and myofibril relaxation still remain elusive. Currently, we are studying this mutation using an integrated experimental-computational approach. We generated triple-mutated cTnI (cTnI-R21C/S2324D) to mimic the phosphorylation. From steady-state fluorescence measurement, which using a fluorescent probe (IANBD) coupled to cTnC C35S , C-I binding affinity (K C-I ) and calcium binding affinity (K Ca ) to whole cTn were monitored. cTnI R21C increased both K C-I and K Ca compared to cTnI WT . Phosphorylation of cTnI reduced K Ca for both complexes. However, while PKA treatment weakened K C-I for cTnI WT , this effect was not absent in cTnI R21C . To study myofibril contraction/relaxation mechanics and kinetics, endogenous cTn was exchanged with either WT or R21C recombinant cTn, and mechanics were monitored at maximum and submaximal Ca 2þ conditions. The kinetics of activation (K ACT ) is slower at submaximal vs maximal Ca 2þ conditions, and not affected by PKA treatment of myofibrils containing either cTnI WT or cTnI R21C . However, PKA treatment of cTn with cTnI WT significantly affected slow phase relaxation, increasing slow phase rate (K REL,slow ) and decreasing slow phase duration (t REL, slow ), and these effects are more clear at submaximal calcium levels. Interestingly, these PKA mediated effects were blunted in cTnI R21C . Molecular dynamics (MD) simulations of whole cTn with R21C and R21C/S23DS24D substitution are ongoing. Interactions between cNTnC-cNTnI, cNTnC-switch peptide of cTnI, and cTnC-inhibitory peptide of cTnI will be monitored, and calcium binding sites will be studied. Computational results will provide the structural basis at molecular level of how R21C influence C-I binding and relaxation of cardiac muscles.
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Actin-Activated Atpase and Actin Sliding Velocities are Similarly Influenced by Actin-Myosin Binding Kinetics Travis J. Stewart, Samuel P. Dugan, Andrew Manfra, Steven Bonzell, Christine R. Cremo, Josh E. Baker. Biochemistry, University of Nevada, Reno, Reno, NV, USA. Detachment-limited models of muscle shortening assume that with increasing myosin densities maximal velocities are achieved when at least one myosin head is bound to a given actin filament. However, numerous studies suggest that actin sliding velocities, V, are influenced by actin-myosin attachment kinetics, suggesting that V should saturate -along with actin-activated myosin ATPase activity, v -when myosin heads saturate binding sites on actin. Here we used an in vitro motility assay to measure both V and v in the same flow cell. We observed that both V and v exhibited similar saturation kinetics with increasing myosin densities and that increasing ionic strength similarly decreased the Km for both activation curves. Using the same in vitro assay, we measured the calcium-dependence of V for regulated thin filaments (actin filaments reconstituted with tropomyosin and troponin) and observed that the myosin-dependence of calcium sensitivity (pCa50) exhibited saturation kinetics similar to that of V and v. These results suggest that saturation of V, v, and pCa50 all occur when myosin saturates binding sites on actin. This is consistent with estimates showing that saturating myosin densities in a motility assay correspond to a linear spacing of myosin along an actin filament that is similar to the repeat of myosin binding sites along one side of the filament. -sensitivity. We studied the effects of small molecules that also modulate Ca 2þ -sensitivity using single thin filaments containing human cardiac troponin in the in vitro motility assay. EMD57033 is a Ca 2þ -sensitiser and causes a dose dependent increase in Ca 2þ -sensitivity (optimum at 30mM). The increase in Ca 2þ -sensitivity was 2-fold for fraction motile and 5-fold for motile velocity. EMD57033 increased Ca 2þ -sensitivity in wild-type, in DCM mutations (TPM1 E40K and E54K) and in troponin from myectomy samples. In addition, in wild-type, Ca 2þ -sensitivity becomes independent of troponin I phosphorylation, this uncoupling resembles the effect of HCM mutations. Epigallocatechin 3-Gallate (EGCG) is a Ca 2þ -desensitiser, 100mM reduces Ca 2þ -sensitivity of native human thin filaments by 1.5-fold. The maximum sliding speed was reduced as well. EGCG also decreased Ca 2þ -sensitivity in thin filaments with DCM mutations (TPM1 E40K and E54K, 1.3-and 3.5-fold respectively) and in troponin from myectomy samples (1.6-fold).
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